You are here

Funding

Duke CFAR Funding Opportunities

Dr. Gunn's Funding Newsletter - November 12, 2018

HIV Vaccine Research Grants for Medical Students
Seeking African American/Black and Latino/a medical students interested in HIV vaccine research

Please follow this link for more information!

 

Prevention of HPV-related Cancers in HIV-infected individuals: United States-Latin American-Caribbean Clinical Trials Network: Partnership Centers (U54 Clinical Trial Required)

  • Participating Organization(s) and Components: National Institutes of Health (NIH), National Cancer Institute (NCI)
  • Purpose:The purpose of this Funding Opportunity Announcement (FOA) is to facilitate the design, conduct, and completion of clinical trials for improving prevention of human papillomavirus (HPV)-related cancers in human immunodeficiency virus (HIV)-infected individuals. To serve this goal, the FOA will support a network of international collaborative sites conducting meritorious and appropriately designed prevention clinical trials in the Latin American and Caribbean (LAC) region via a U54 Partnership Centers mechanism.
    Each proposed U54 Partnership Center must be based on a collaboration between a research institution in the United States (as the applicant institution) and partnering institution(s) in low- and middle-income countries (LMICs) in the LAC region. The proposed clinical trials should be focused on optimizing clinical prevention interventions among HIV-infected individuals, including immunoprevention (vaccination), screening and triage, and precancer treatment.
    Each Partnership Center application must propose a Clinical Trials Program that will develop and conduct three prevention clinical trials within the 5-year project period. As infrastructure supporting the Clinical Trials Program, each Partnership Center should include an Administrative and Coordinating Core, a Data Management and Statistical Core, and a Central Laboratory Core. Results of the clinical trials conducted through the Partnership Centers are expected to influence the development of clinical practice guidelines to improve preventive clinical care and reduce the burden of highly preventable HPV-related cancers in HIV-infected individuals. 
  • Open Date: October 15, 2018
  • Amount of Award: NCI intends to commit a total of $4.45 million in FY 2019 to fund up to two (2) awards. Application budgets should be commensurate with the scope of the research activities proposed but must not exceed $1.5 million per year in direct costs.
  • Due Date: November 15, 2018, by 5:00 PM local time of applicant organization
  • More Information: https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-18-018.html
  • End Date: November 16, 2018

 

High Priority HIV/AIDS Research within the Mission of the NIDDK (R01 Clinical Trial Optional)

 

Research on Comparative Effectiveness and Implementation of HIV/AIDS and Alcohol Interventions (R01 Clinical Trial Optional)

  • Participating Organization(s) and Components: National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism (NIAAA)
  • Purpose: HIV+ alcohol users remain at high risk for medication non-adherence and rapid disease progression, medication toxicities, organ failure, and poor viremic control, leading to increased risk of transmission and premature death. Recent advances in technology and biomedical science (e.g., new pharmacological agents, alcohol and inflammation biomarkers, internet and mobile technology) open new opportunities for strengthening the quality of HIV/alcohol-related implementation research through utilization of novel technology and biomarkers. This initiative seeks to advance knowledge on implementation and comparative effectiveness of alcohol-focused interventions among HIV+ individuals. Multiple factors need to be investigated, including potentially important patient and provider characteristics, and the organizational, financial, and structural factors that facilitate or inhibit the delivery of evidence-based services for HIV+ individuals with a range of severity of alcohol use problems. The overall goal is to inform clinical decision-making to implement effective interventions that will improve prevention, care, and outcomes across the continuum of HIV and alcohol problem severity and patterns of alcohol use. This solicitation is divided into two major topics. An application may choose to address one or both. These topics include: 1) comparative effectiveness research focused on understanding factors related to early detection, patient engagement and retention in appropriate alcohol and HIV care, and achieving and maintaining optimal treatment responses in diverse settings, and 2) modeling and testing alternative implementation approaches to improve uptake and scaling-up of effective interventions and reduce HIV disease transmission and progression.
  • Open Date: January 5, 2018
  • Amount of Award: NIH intends to fund an estimate of 4-6 awards, corresponding to a total of $3 million per year, for fiscal year 2018 to 2022.
  • Due Date: Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. 
    Standard AIDS dates apply), by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates.
  • More Information: https://grants.nih.gov/grants/guide/pa-files/PAS-18-557.html
  • End Date: May 8, 2020

 

Detection of HIV for Self-Testing (R61/R33)

  • Participating Organization(s) and Components: National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Mental Health (NIMH)
  • Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to support bi-phasic developmental, discovery-driven, or hypothesis-driven research focused on innovative strategies to detect HIV either within the first two weeks of infection or to monitor viral rebound after stopping or developing resistance to antiretroviral therapy. Applications should propose simple diagnostic tools that would be feasible for a self-testing platform to allow untrained individuals to detect HIV. Interdisciplinary collaborations that include biomedical, physical, and behavioral sciences are highly encouraged.    
  • Open Date: November 6, 2017
  • Amount of Award: NIAID intends to commit $2,640,000 in FY 2018 to fund 3-6 awards. NIMH intends to commit $300,000 total cost in FY 2018.  Future year amounts will depend on annual appropriations. 
  • Due Date: December 6, 2017, December 6, 2018, and December 6, 2019 , by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
    December 6, 2017, December 6, 2018, and December 6, 2019, by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates.
  • More Information: https://grants.nih.gov/grants/guide/pa-files/PAR-17-471.html
  • End Date: December 7, 2019

 

Phylodynamic Tracking of HIV Transmission (R01)

  • Participating Organization(s) and Components: National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH)
  • Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to support interdisciplinary research collaborations to study and optimize approaches using phylodynamic analyses of HIV genotyping databases to monitor HIV transmission networks in near real-time. The long-range goal is to leverage existing databases and support innovations in HIV phylodynamics to better inform testing, treatment, and prevention efforts. 
  • Open Date: February 15, 2017 
  • Amount of Award: NIH intends to fund an estimate of 4-7 awards, corresponding to a total of $4.39 M, for fiscal year 2018. Future year amounts will depend on annual appropriations.
  • Due Date: March 15, 2017; March 15, 2018; March 15, 2019  , by 5:00 PM local time of applicant organization. All types of applications allowed for this funding opportunity announcement are due on these dates.
  • More Information: https://grants.nih.gov/grants/guide/pa-files/PAR-17-048.html
  • End Date: March 16, 2019

 

"High" or "Medium" Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers (R01)

  • Participating Organization(s) and Components: National Institutes of Health (NIH), National Cancer Institute (NCI), National Institute of Dental and Craniofacial Research (NIDCR)
  • Purpose: The purpose of this funding opportunity announcement (FOA) is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency (HIV) infection or acquired immunodeficiency syndrome (AIDS), particularly the non-AIDS defining malignancies which are now a leading cause of death in HIV-infected individuals. 
    This FOA encourages high or medium priority AIDS research in areas such as the study of the etiologic factors, cofactors, immunopathogenesis, diagnosis, and consequences of both non-AIDS defining and AIDS-defining malignancies in populations with an underlying HIV infection.
    This FOA encourages research efforts that will (i) identify specific contributions resulting from HIV infection and its potential interaction with other pathogens for the development and pathogenesis of these cancers and (ii) provide information on the clinical outcomes of such cancers in the HIV-infected population. Ultimately, such efforts could inform screening approaches and therapies targeted to the HIV-infected population.   
  • Open Date: December 7, 2016
  • Amount of Award: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
  • Due Date: January 7, 2017
  • More Information: https://grants.nih.gov/grants/guide/pa-files/PA-16-426.html
  • End Date: September 8, 2019

 

"High" or "Medium" Priority AIDS Research  on Non-AIDS-defining or AIDS-defining Cancers (R21)

  • Participating Organization(s) and Components: National Institutes of Health (NIH), National Cancer Institute (NCI), National Institute of Dental and Craniofacial Research (NIDCR)
  • Purpose: The purpose of this funding opportunity announcement (FOA) is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency (HIV) infection or acquired immunodeficiency syndrome (AIDS), particularly the non-AIDS defining malignancies which are now a leading cause of death in HIV-infected individuals.  
    This FOA encourages high or medium priority AIDS research in areas such as the study of the etiologic factors, cofactors, immunopathogenesis, diagnosis, and consequences of both non-AIDS defining and AIDS-defining malignancies in populations with an underlying HIV infection. 
    This FOA encourages research efforts that will (i) identify specific contributions resulting from HIV infection and its potential interaction with other pathogens for the development and pathogenesis of these cancers and (ii) provide information on the clinical outcomes of such cancers in the HIV-infected population. Ultimately, such efforts could inform screening approaches and therapies targeted to the HIV-infected population.   
  • Open Date: December 7, 2016
  • Amount of Award: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
  • Due Date: January 7, 2017
  • More Information: https://grants.nih.gov/grants/guide/pa-files/PA-16-425.html
  • End Date: September 8, 2019

 

Apply now for the UCSF CAPS Visiting Professors Program

The UCSF Center for AIDS Prevention Studies (CAPS) has a Visiting Professors program to train investigators in conducting research with ethnic minority communities. The VP Program is designed to assist investigators already conducting HIV-prevention research with minority communities to improve their programs of research and obtain additional funding for their work. It includes a 6-week summer residency, pilot funding, and other mentorship and career development opportunities. More information is described below and at their website: http://vp.ucsf.edu/.